124 related articles for article (PubMed ID: 8620520)
1. Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells.
Rosenblum MG; Cheung L; Kim SK; Mujoo K; Donato NJ; Murray JL
Cancer Immunol Immunother; 1996 Feb; 42(2):115-21. PubMed ID: 8620520
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin.
Mujoo K; Cheung L; Murray JL; Rosenblum MG
Cancer Immunol Immunother; 1995 May; 40(5):339-45. PubMed ID: 7600567
[TBL] [Abstract][Full Text] [Related]
3. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
Rosenblum MG; Marks JW; Cheung LH
Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
[TBL] [Abstract][Full Text] [Related]
4. A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2.
Mujoo K; Reisfeld RA; Cheung L; Rosenblum MG
Cancer Immunol Immunother; 1991; 34(3):198-204. PubMed ID: 1756537
[TBL] [Abstract][Full Text] [Related]
5. A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin.
Rosenblum MG; Murray JL; Cheung L; Rifkin R; Salmon S; Bartholomew R
Mol Biother; 1991 Mar; 3(1):6-13. PubMed ID: 1906286
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of cellular trafficking and cytotoxicity of 9.2.27-gelonin immunotoxins targeted against the high-molecular-weight melanoma-associated antigen.
Chan MC; Murphy RM
Cancer Immunol Immunother; 1999 Feb; 47(6):321-9. PubMed ID: 10203062
[TBL] [Abstract][Full Text] [Related]
7. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin.
Rosenblum MG; Cheung LH; Liu Y; Marks JW
Cancer Res; 2003 Jul; 63(14):3995-4002. PubMed ID: 12873997
[TBL] [Abstract][Full Text] [Related]
8. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
[TBL] [Abstract][Full Text] [Related]
9. A gelonin-containing immunotoxin directed against human breast carcinoma.
Rosenblum MG; Zuckerman JE; Marks JW; Rotbein J; Allen WR
Mol Biother; 1992 Sep; 4(3):122-9. PubMed ID: 1445665
[TBL] [Abstract][Full Text] [Related]
10. Photochemical internalisation increases the cytotoxic effect of the immunotoxin MOC31-gelonin.
Selbo PK; Sivam G; Fodstad O; Sandvig K; Berg K
Int J Cancer; 2000 Sep; 87(6):853-9. PubMed ID: 10956397
[TBL] [Abstract][Full Text] [Related]
11. An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models.
Rosenblum MG; Cheung L; Mujoo K; Murray JL
Cancer Immunol Immunother; 1995 May; 40(5):322-8. PubMed ID: 7600565
[TBL] [Abstract][Full Text] [Related]
12. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.
Pirie CM; Hackel BJ; Rosenblum MG; Wittrup KD
J Biol Chem; 2011 Feb; 286(6):4165-72. PubMed ID: 21138845
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of antiproliferative effects of monoclonal antibody Lym-1 and immunoconjugate Lym-1-gelonin on human Burkitt's lymphoma cells with gamma-interferon and tumor necrosis factor.
O'Boyle KP; Colletti D; Mazurek C; Wang Y; Ray SK; Diamond B; Rosenblum MG; Epstein AL; Shochat D; Dutcher JP
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):221-30. PubMed ID: 8680650
[TBL] [Abstract][Full Text] [Related]
14. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
[TBL] [Abstract][Full Text] [Related]
15. 5-Aminolevulinic acid-based photochemical internalization of the immunotoxin MOC31-gelonin generates synergistic cytotoxic effects in vitro.
Selbo PK; Kaalhus O; Sivam G; Berg K
Photochem Photobiol; 2001 Aug; 74(2):303-10. PubMed ID: 11547569
[TBL] [Abstract][Full Text] [Related]
16. Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule.
Myers DE; Yanishevski Y; Masson E; Irvin JD; Evans WE; Uckun FM
Leuk Lymphoma; 1995 Jun; 18(1-2):93-102. PubMed ID: 8580835
[TBL] [Abstract][Full Text] [Related]
17. Antiviral immunotoxins: antibody-mediated delivery of gelonin inhibits Pichinde virus replication in vitro.
Barnett BB; Burns NJ; Park KJ; Dawson MI; Kende M; Sidwell RW
Antiviral Res; 1991 Feb; 15(2):125-38. PubMed ID: 1650165
[TBL] [Abstract][Full Text] [Related]
18. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
19. Immunotoxin resistance in multidrug resistant cells.
McGrath MS; Rosenblum MG; Philips MR; Scheinberg DA
Cancer Res; 2003 Jan; 63(1):72-9. PubMed ID: 12517780
[TBL] [Abstract][Full Text] [Related]
20. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.
Wenning LA; Murphy RM
Biotechnol Bioeng; 1999 Mar; 62(5):562-75. PubMed ID: 10099565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]